A significant upregulation of syndecan-1 and a positive correlation with the expression of CD44, a marker of cancer stem cell (CSC) phenotype, have been documented in inflammatory breast cancer, a particularly aggressive BC subtype. Here, CD44 is linked to breast cancer.